Evaluación de la función cognitiva en pacientes de edad avanzada con vejiga hiperactiva tratados con oxibutinina transdémica / Cognitive function assessment in elderly patients with overactive bladder treated with transdermal oxybutynin

Introducción y objetivos: Los pacientes mayores con vejiga hiperactiva bajo tratamiento antimuscarínico son especialmente susceptibles al deterioro cognitivo. El objetivo fue evaluar los cambios a corto plazo en la función cognitiva de pacientes de edad avanzada con vejiga hiperactiva tratados con oxibutinina transdérmica. Materiales y métodos: Estudio observacional retrospectivo multicéntrico en pacientes entre 65 y 80 años de edad, con vejiga hiperactiva, que reciben tratamiento con oxibutinina transdérmica. Antes y después de un mes de tratamiento, se evaluó la función cognitiva mediante el test de alteración de memoria y el test del dibujo del reloj, los cambios en los síntomas con cuestionarios validados, la percepción del paciente ante su respuesta al tratamiento utilizando la escala de beneficio del tratamiento y la adherencia al tratamiento con el test de Morisky-Green modificado. Resultados: De 85 pacientes elegibles, 70 completaron la evaluación (promedio de edad: 71,4 ± 4,5; IMC: 28,7 ± 3,1 kg/m2). No se observó deterioro cognitivo tras un mes de tratamiento con oxibutinina transdérmica: Test de alteración de memoria (+1 punto; IC 95%: 0-1,5), test del dibujo del reloj (0 puntos; IC 95%: 0-0). Se observó una mejoría estadísticamente significativa (p < 0,001) en todos los síntomas de almacenamiento urinario, excepto en la incontinencia de esfuerzo. Hubo una mejora en el cuestionario de autoevaluación de control de la vejiga (grado de los síntomas: -2,27; IC 95%: -2,8, -1,7; p < 0,001; grado de molestias: -2,73; IC 95%: -3,3, -2,1; p < 0,001). El 70% de los pacientes informaron una condición de vejiga estable o mejorada según el cuestionario de Percepción de la Condición de la Vejiga del Paciente. El 72,8% de los pacientes informó que sus problemas urinarios habían mejorado o mejorado notablemente con un 84,3% de adherencia al tratamiento. Conclusiones: No se observó deterioro cognitivo en pacientes de edad avanzada tras de un mes de tratamiento con oxibutinina transdérmica. Los síntomas de incontinencia urinaria mejoraron y hubo una adecuada adherencia al tratamiento

Introduction and objectives: Older patients with overactive bladder under antimuscarinic treatment are especially susceptible to cognitive impairment. The aim was to assess short term changes in cognitive function in elderly patients with overactive bladder treated with transdermal oxybutynin. Materials and methods: Observational, retrospective, multicentre study in patients with overactive bladder aged 65-80 years undergoing treatment with transdermal oxybutynin. Before and after one month of treatment, cognitive function using the Memory Alteration Test and Clock-Drawing Test, changes in symptoms with validated questionnaires, patient perception of treatment response using Treatment Benefit Scale and treatment adherence with the modified Morisky-Green test, were assessed. Results: From 85 eligible patients, 70 completed the assessment (mean age: 71.4 ± 4.5; BMI: 28.7 ± 3.1 kg/m2). No cognitive impairment was observed after one month with transdermal oxybutynin: Memory Alteration Test (+1 point; 95%CI: 0.0-1.5), Clock-Drawing Test (0 points; 95%CI: 0.0-0.0). A statistically significant improvement (p < 0.001) was observed in all urinary storage symptoms, except stress urinary incontinence. There was an improvement in the Bladder Control Self-Assessment Questionnaire (symptom score: -2.27; 95%CI: -2.8, -1.7; p < 0.001; bother score: -2.73; 95%CI: -3.3, -2.1; p < 0.001). 70% of patients reported either a stable or improved bladder condition according to the Patient Perception of Bladder Condition questionnaire. 72.8% of patients reported that their urinary problems had improved or greatly improved with an 84.3% treatment adherence. Conclusions: No cognitive impairment was observed in elderly patients after one month of treatment with transdermal oxybutynin; urinary urgency symptoms improved and there was adequate treatment adherence

Síndrome de dolor vesical: prevalencia y práctica clínica habitual en mujeres que acuden a Unidades de Urología Funcional y Urodinámica en España / Bladder pain syndrome: Prevalence and routine clinical practice in women attending functional urology and urodynamics units in Spain

Introducción y objetivos: El síndrome de dolor vesical (SDV) está catologado como enfermedad rara y su diagnóstico representa un desafío debido al solapamiento de sus síntomas con los asociados al síndrome de vejiga hiperactiva. El objetivo fue estimar la prevalencia del SDV y conocer el perfil de síntomas y la práctica clínica en pacientes que acuden a unidades de Urología Funcional y Urodinámica. Material y métodos: Estudio epidemiológico en el cual participaron 37 unidades de Urología Funcional y Urodinámica de España. La prevalencia se estudió considerando ambos sexos. Se evaluó la práctica clínica en 319 mujeres con SDV (nuevo diagnóstico o en revisión). Se recogieron retrospectivamente datos clínicos y sociodemográficos. Se analizaron los resultados de análisis de orina, cistoscopia, biopsia, exploración física, diario miccional, así como de los 4 cuestionarios disponibles: Patient Perception of Bladder Condition; Bladder Pain/Interstitial Cystitis Symptom Score; EuroQoL-5 Dimensions-5L y Patient Global Impression of Severity. Resultados: El 5,4% (503) de los pacientes que acudieron a estas unidades (9.312) tenían diagnóstico de SDV (90% [453] mujeres). Las pruebas más realizadas según historia clínica y anamnesis fueron: análisis de orina, ecografía vesical y cistoscopia. Los síntomas/comorbilidades más frecuentes fueron: dolor en la región vesical, frecuencia miccional aumentada, nicturia, ansiedad y depresión. La evaluación diagnóstica determinó dolor en hidrodistensión (86,9%), biopsia positiva (59,2%), dolor miofascial pélvico (28,4%), fenotipo urológico (97,8%) y frecuencia miccional aumentada (88,7%). Los cuestionarios reflejaron el elevado grado de afectación de la calidad de vida de estos pacientes. Conclusiones: La prevalencia del SDV en las unidades de Urología Funcional y Urodinámica en España es baja. No se observa homogeneidad en cuanto al diagnóstico entre los diferentes centros participantes. Por ello, sería necesario establecer una metodología común de manejo de pacientes con SDV en estas unidades, con herramientas específicas para esta patología

Introduction and objectives: Bladder pain syndrome (BPS) is classified as a rare chronic debilitating disease and its diagnosis presents a challenge because its symptoms overlap with those associated with overactive bladder syndrome. The aim of the routine study was to estimate the prevalence of BPS and discover to study the profile of symptoms and clinical practice for patients attending functional urology and urodynamics units. Material and methods: An epidemiological study in which 37 functional urology and urodynamics units in Spain participated. The prevalence was studied in both sexes. Clinical practice was evaluated for 319 women with BPS (new diagnosis or under review). Clinical and sociodemographic data were collected retrospectively. The results were studied of urine tests, cystoscopy, biopsy, physical examination, bladder diary, and those of the four available questionnaires: Patient Perception of Bladder Condition; Bladder Pain/Interstitial Cystitis Symptom Score; EuroQoL-5 Dimensions-5L and Patient Global Impression of Severity. Results: Five point four percent (503) of the patients who attended these units (9,312) had a diagnosis of BPS (90% [453] females). The tests that were performed most according to the clinical history and anamnesis were: urine test, bladder ultrasound and cystoscopy. The most common symptoms/comorbidities were: pain in the bladder region, increased urinary frequency, nocturia, anxiety and depression. Diagnostic assessment determined pain on hydrodistension (86.9%), positive biopsy (59.2%), myofascial pelvic pain (28.4%), urological phenotype (97.8%), and increased urinary frequency (88.7%). The questionnaires reflected how much the quality of life of these patients was affected. Conclusions: The prevalence of BPS in functional urology and urodynamics units in Spain is low. No homogeneity was observed in terms of diagnosis between the different participating centres. Therefore, a common methodology is required for the management of patients with BPS in these units, with tools specific to this disorder

Bladder pain syndrome: Prevalence and routine clinical practice in women attending functional urology and urodynamics units in Spain. / Síndrome de dolor vesical: prevalencia y práctica clínica habitual en mujeres que acuden a Unidades de Urología Funcional y Urodinámica en España.

INTRODUCTION AND OBJECTIVES: Bladder pain syndrome (BPS) is classified as a rare chronic debilitating disease and its diagnosis presents a challenge because its symptoms overlap with those associated with overactive bladder syndrome. The aim of the routine study was to estimate the prevalence of BPS and discover to study the profile of symptoms and clinical practice for patients attending functional urology and urodynamics units. MATERIAL AND METHODS: An epidemiological study in which 37 functional urology and urodynamics units in Spain participated. The prevalence was studied in both sexes. Clinical practice was evaluated for 319 women with BPS (new diagnosis or under review). Clinical and sociodemographic data were collected retrospectively. The results were studied of urine tests, cystoscopy, biopsy, physical examination, bladder diary, and those of the four available questionnaires: Patient Perception of Bladder Condition; Bladder Pain/Interstitial Cystitis Symptom Score; EuroQoL-5 Dimensions-5L and Patient Global Impression of Severity. RESULTS: Five point four percent (503) of the patients who attended these units (9,312) had a diagnosis of BPS (90% [453] females). The tests that were performed most according to the clinical history and anamnesis were: urine test, bladder ultrasound and cystoscopy. The most common symptoms/comorbidities were: pain in the bladder region, increased urinary frequency, nocturia, anxiety and depression. Diagnostic assessment determined pain on hydrodistension (86.9%), positive biopsy (59.2%), myofascial pelvic pain (28.4%), urological phenotype (97.8%), and increased urinary frequency (88.7%). The questionnaires reflected how much the quality of life of these patients was affected. CONCLUSIONS: The prevalence of BPS in functional urology and urodynamics units in Spain is low. No homogeneity was observed in terms of diagnosis between the different participating centres. Therefore, a common methodology is required for the management of patients with BPS in these units, with tools specific to this disorder.

Cognitive function assessment in elderly patients with overactive bladder treated with transdermal oxybutynin. / Evaluación de la función cognitiva en pacientes de edad avanzada con vejiga hiperactiva tratados con oxibutinina transdémica.

INTRODUCTION AND OBJECTIVES: Older patients with overactive bladder under antimuscarinic treatment are especially susceptible to cognitive impairment. The aim was to assess short term changes in cognitive function in elderly patients with overactive bladder treated with transdermal oxybutynin. MATERIALS AND METHODS: Observational, retrospective, multicentre study in patients with overactive bladder aged 65-80 years undergoing treatment with transdermal oxybutynin. Before and after one month of treatment, cognitive function using the Memory Alteration Test and Clock-Drawing Test, changes in symptoms with validated questionnaires, patient perception of treatment response using Treatment Benefit Scale and treatment adherence with the modified Morisky-Green test, were assessed. RESULTS: From 85 eligible patients, 70 completed the assessment (mean age: 71.4±4.5; BMI: 28.7±3.1kg/m2). No cognitive impairment was observed after one month with transdermal oxybutynin: Memory Alteration Test (+1 point; 95%CI: 0.0-1.5), Clock-Drawing Test (0 points; 95%CI: 0.0-0.0). A statistically significant improvement (P<.001) was observed in all urinary storage symptoms, except stress urinary incontinence. There was an improvement in the Bladder Control Self-Assessment Questionnaire (symptom score: -2.27; 95%CI: -2.8, -1.7; P<.001; bother score: -2.73; 95%CI: -3.3, -2.1; P<.001). 70% of patients reported either a stable or improved bladder condition according to the Patient Perception of Bladder Condition questionnaire. 72.8% of patients reported that their urinary problems had improved or greatly improved with an 84.3% treatment adherence. CONCLUSIONS: No cognitive impairment was observed in elderly patients after one month of treatment with transdermal oxybutynin; urinary urgency symptoms improved and there was adequate treatment adherence.

Inyección de la toxina botulínica en el esfínter urinario: experiencia y resultados / The use of botulinum toxin in urinary sphincter: Experience and outcomes

Objetivo. Presentamos la experiencia de nuestro centro con la inyección de la toxina botulínica tipo A (TB) en el esfínter urinario de los pacientes con disfunción de vaciado. Material y método. Se inyectó TB en el esfínter urinario a 20 pacientes entre diciembre de 2003 y agosto de 2011 para el tratamiento de distintas disfunciones de vaciado refractarias a tratamiento convencional. Se utilizaron 4 vías de inyección: transuretral, parameatal en mujeres, transrectal en varones y transvaginal. Las dosis utilizadas oscilaron entre 50 y 200U. Resultados. Obtuvimos resultados satisfactorios en 11 pacientes (55%) según criterios clínicos. La duración del efecto osciló entre los 3 y 7 meses. No registramos complicaciones significativas relacionadas con la inyección, y la tolerancia al dolor fue buena. Conclusiones. La inyección de TB en el esfínter urinario es una técnica segura y eficaz para el tratamiento de diversos trastornos del tracto urinario inferior, pero sus resultados deben interpretarse cautelosamente, sobre todo en función de los parámetros utilizados para medir la eficacia (AU)

Objective. We present the experience of our center with the injection of type A botulinum toxin (BT) in urinary sphincter in patients with voiding dysfunction. Material and methods. BT was injected in the urinary sphincter of 20 patients between December 2003 and August 2011 in order to treat different voiding dysfunctions refractory to conventional treatment. Four injection methods were used: transurethral, paraurethral, transrectal and transvaginal. The doses used ranged from 50 to 200 units. Results. Satisfactory outcomes were obtained in 11 patients (55%) according to the clinical criteria. The effect lasted from 3 to 7 months. No major complications were registered and pain tolerance was good. Conclusions. The injection of BT in the urinary sphincter is safe and effective for the treatment of different lower urinary tract disorders, however its results should be interpreted with caution, above all based on the parameters used to measure the efficacy (AU)

Análisis del valor pronóstico de la trombosis tumoral venosa en el adenocarcinoma renal / Prognostic value of venous tumor thrombus in renal cell carcinoma

Objetivo: Analizar el valor pronóstico de la trombosis tumoral venosa en el carcinoma de células renales (CCR).Material y métodos: Estudio retrospectivo de 167 pacientes con carcinoma de células renales (estadio pT3) intervenidos mediante nefrectomía radical y linfadenectomía (julio de 1969 a mayo de 2008). Para el análisis se seleccionaron los pacientes con afectación venosa (73 pacientes; 43,7%). Para el análisis de supervivencia, se utilizaron las curvas de Kaplan-Meyer y el test de log-rank. El análisis multivariante se realizó mediante regresión de Cox. Resultados: En 30 pacientes (41,1%) existía afectación ganglionar, y en 9 pacientes (12,3%) enfermedad metastásica. El subtipo histológico más frecuente fue el carcinoma convencional en 50 pacientes (68,5%), seguido del indiferenciado en 11 pacientes (15,5%) y el cromófobo en 9 pacientes (12,3%). El 57% de los tumores fueron de alto grado (Furhman 3-4). El nivel de trombotumoral se extendía hasta la vena renal en 61 pacientes (83,6%), hasta la cava infradiafragmática en 9 pacientes (12,3%), y en 3 casos (4,1%) al atrio. El análisis de supervivencia mostró peor supervivencia en aquellos pacientes con trombosis tumoral venosa (p=0,001) y con invasión de la pared venosa (p=0,0042) pero no en función del nivel del trombo (p= 0,12). El análisis multivariante identificó el grado de Furhman y la trombosis tumoral venosa como factores pronósticos independientes de supervivencia. Conclusiones: En nuestra serie la trombosis tumoral venosa es un factor pronóstico independiente de supervivencia, junto al grado nuclear de Furhman. Ni el nivel de extensión cefálica del trombo ni la invasión de la pared venosa mostraron valor pronóstico independiente (AU)

Objective: To evaluate the prognostic value of venous tumor thrombus in renal cell carcinoma. Material and methods: A retrospective study of 167 patients with renal cell carcinoma and stage pT3 who underwent radical nephrectomy and extended lymphadenectomy from July 1969 to May 2008 was conducted. Patients with any kind of venous involvement were selected for the analysis (73 patients; 43.7%). The Kaplan Meier survival curves and log-rank test for comparisons were used for the survival analysis. Multivariate analysis was done by Coxregression. Results: Lymph node involvement was present in 30 patients (41.1%) and metastatic disease in9 patients (12.3%). The most frequent histologic renal cell carcinoma subtype was 50 (68.5%) conventional carcinoma, followed by non differentiated in 11 (15.5%), and chromophobe in9 (12.3%). High grade tumors (Furhman 3-4) were present in 57% of the cases. Venous thrombus level extended to renal vein in 61 patients (83.6%), to inferior vena cava in 9 patients (12.3%) and to the cardiac right atrium in 3 cases (4.1%). The survival analysis showed worse survival in those patients with venous tumor thrombosis (p=.001) and with vein wall invasion (p=0.0042), but not in function on the level of the thrombus (p=0.12). The multivariate analysis identified the Furhman grade and venous tumor thrombosis as independent survival prognostic factors. Conclusions: In our series, venous tumor thrombosis, together with the Furhman nuclear grade, is an independent survival prognostic factor. However, neither cephalic extension of the thrombusn or the invasion of the vein wall showed independent prognostic value (AU)

[Prognostic value of venous tumor thrombus in renal cell carcinoma]. / Análisis del valor pronóstico de la trombosis tumoral venosa en el adenocarcinoma renal.

OBJECTIVE: To evaluate the prognostic value of venous tumor thrombus in renal cell carcinoma. MATERIAL AND METHODS: A retrospective study of 167 patients with renal cell carcinoma and stage pT3 who underwent radical nephrectomy and extended lymphadenectomy from July 1969 to May 2008 was conducted. Patients with any kind of venous involvement were selected for the analysis (73 patients; 43.7%). The Kaplan Meier survival curves and log-rank test for comparisons were used for the survival analysis. Multivariate analysis was done by Cox regression. RESULTS: Lymph node involvement was present in 30 patients (41.1%) and metastatic disease in 9 patients (12.3%). The most frequent histologic renal cell carcinoma subtype was 50 (68.5%) conventional carcinoma, followed by nondifferentiated in 11 (15.5%), and chromophobe in 9 (12.3%). High grade tumors (Furhman 3-4) were present in 57% of the cases. Venous thrombus level extended to renal vein in 61 patients (83.6%), to inferior vena cava in 9 patients (12.3%) and to the cardiac right atrium in 3 cases (4.1%). The survival analysis showed worse survival in those patients with venous tumor thrombosis (p=.001) and with vein wall invasion (p=.0042), but not in function on the level of the thrombus (p=.12). The multivariate analysis identified the Furhman grade and venous tumor thrombosis as independent survival prognostic factors. CONCLUSIONS: In our series, venous tumor thrombosis, together with the Furhman nuclear grade, is an independent survival prognostic factor. However, neither cephalic extension of the thrombus nor the invasion of the vein wall showed independent prognostic value.

Alternativas a la vía transuretral para la inyección de toxina botulínica en esfínter urinario / Botulinum toxin inyection in urinary sphincter: alternative approaches

Objetivo: Presentamos las vías transrectal en varones y transvaginal en mujeres como alternativas a la vía transuretral para la inyección de toxina botulínica (TB) en esfínter urinario, así como nuestros resultados. Material y Método: Se inyectó TB en esfínter urinario a 9 pacientes entre diciembre de 2008 y agosto de 2010para el tratamiento de distintas disfunciones de vaciado refractarias a tratamiento convencional. La vía utilizada fue transrectal en 7 varones y transvaginal en 2 mujeres. Las dosis utilizadas oscilaron entre 50 y200 U. Registramos resultados y complicaciones. Resultados: Obtuvimos resultados satisfactorios en 6pacientes (66 por ciento) según criterios clínicos. La duración del efecto osciló entre los 3 y 7 meses. No registramos complicaciones significativas relacionadas con la inyección y la tolerancia al dolor fue buena. Conclusiones: La vía transrectal en varones y transvaginal en mujeres son alternativas válidas y seguras para la inyección de TB en esfínter urinario.

Objective: To present our institution experience and outcomes with transrectal and transvaginal injection of botulinum toxin (TB) in urinary sphincter to treat voiding disfunction. Material and methods: We injected TB in 9 patients since December 2008 to august 2010 in order to treat different voiding disfunctions. We use the transrectal approach in 7 men and the transvaginal method in 2 women. The dose used ranged from 50 to 200 units. Outcomes and complications were registered. Results: Satisfactory outcomes were obtained in 6 patients (66 pert cent) according to clinical criteria. The duration of the effect was from 3 to 7 months. No major complications were registered and pain was well tolerated. Conclusions: Transrectal and transvaginal approaches are effective and safe for the injection of TB in urinary sphincter.

Liposarcoma desdiferenciado de alto grado de cordón espermático. A propósito de un caso / High grade dedifferenciated liposarcoma. Case report and review of the literature

No disponible

No disponible

Análisis de la adherencia de los urólogos españoles a las recomendaciones de diagnóstico y tratamiento de las guías de práctica clínica sobre incontinencia urinaria / Analysis of the spanish urologists adherence to the recomendations of the guidelines on diagnostic and treatment of urinary incontinence

Objetivo: Ante la carencia de datos sobre el grado de adherencia a las guías clínicas sobre incontinencia urinaria, el objetivo fue conocer cómo la diagnostican y tratan los urólogos españoles. Material y métodos: Sondeo de opinión quasi nacional sobre 202 urólogos en 20 reuniones representativas. Se realizaron 2 preguntas de diagnóstico y 2 de tratamiento, agrupando las respuestas por concepto. Se uso el método Grupo Focal dinamizado con 'brain storming estructurado'. La adherencia se estimó por la concordancia entre lo recomendado y lo practicado. Los resultados se promediaron según el total de respuestas. Resultados: La adherencia fue: anamnesis 88%, exploración física 78%, analítica 47%, sedimento 72% y cultivo 67%. Para la urodinámica fue del 23% y para el uso de cuestionarios de síntomas y calidad de vida fue minoritaria con 14% y 26%. La adherencia a preguntas correctas sobre el tipo de incontinencia fue muy elevada, necesitándose sólo 2,7 preguntas de media para el diagnóstico correcto. En el tratamiento de la incontinencia mixta, un 85% abordó primero la urgencia y un 11% el esfuerzo. El 27% considera que el principal motivo es la disponibilidad de drogas. Para el tratamiento de la incontinencia de urgencia, la adherencia al uso de antimuscarínicos fue del 98% y la de la modificación de hábitos del 50%. En la incontinencia de esfuerzo, la adherencia en el uso de ejercicios del suelo pélvico fue del 81% y para la cirugía del 53%. Conclusiones: La adherencia de los urólogos españoles a las guías de IU está lejos de lo ideal. Aún con sesgos, los resultados pueden considerarse representativos. Es deseable que, en la creación de guías, se diseñen indicadores que midan el grado de adherencia

Objetive: Data regarding the degree of adherence to urinary incontinence guidelines are not available. The aim of this study was to know how the spanish urologist diagnos and treat urinary incontinence. Material and methods: This is an opinion poll from 202 urologist underwent in 20 representative meetings of the Spain. The poll consisted of 2 questions about diagnostic and 2 about treatment of urinary incontinence. The anwsers were grouped by ideas. The focal group method dinamized by “structured brain storming” was used. We evaluate the adherence to the incontinence guide lines analizing the agreement between the recommendations and the real practice. We average acording all obtained responses. Results: The adherence were: history 88%, physical examination 78%, blood test 47%, urunalysis 72% and urine culture 67%. The adherence for urodynamic investigation was 23%. The use of symptom and quality of life cuestionares was minority (14% y 26%). The adherence to the right questions about the type of incontinece was very high. An average of 2.7 questions to reach correct diagnoses was needed. A 85% of urologist treat urge compenent of mixed incontinence firstly and 11% the stress component. The 27% considered the availability of drug as the main reason for such prioritization. The adherence of treating urge incontinence with antimuscarics was 98% and of life style interventions 50%. For treating stress urinary incontinence, the adherence to pelvic floor muscle training was 81% and to surgery 53%. Conclusions: Spanish urologist adherence to incontinence urinary guidelines is far from the ideal. Although this study may have bias, the outcome can be considered as representative of the situation. It is desirable that, in the process of guidelines creation, specific parameters to assess the degree of adherence be designed

[Analysis of the spanish urologists adherence to the recomendations of the guidelines on diagnostic and treatment of urinary incontinence]. / Análisis de la adherencia de los urólogos españoles a las recomendaciones de diagnóstico y tratamiento de las guías de práctica clínica sobre incontinencia urinaria.

OBJECTIVE: [corrected] Data regarding the degree of adherence to urinary incontinence guidelines are not available. The aim of this study was to know how the spanish urologist diagnos and treat urinary incontinence. MATERIAL AND METHODS: This is an opinion poll from 202 urologist underwent in 20 representative meetings of the Spain. The poll consisted of 2 questions about diagnostic and 2 about treatment of urinary incontinence. The anwsers were grouped by ideas. The focal group method dinamized by "structured brain storming" was used. We evaluate the adherence to the incontinence guide lines analizing the agreement between the recommendations and the real practice. We average acording all obtained responses. RESULTS: The adherence were: history 88%, physical examination 78%, blood test 47%, urunalysis 72% and urine culture 67%. The adherence for urodynamic investigation was 23%. The use of symptom and quality of life cuestionares was minority (14% y 26%). The adherence to the right questions about the type of incontinece was very high. An average of 2.7 questions to reach correct diagnoses was needed. A 85% of urologist treat urge compenent of mixed incontinence firstly and 11% the stress component. The 27% considered the availability of drug as the main reason for such prioritization. The adherence of treating urge incontinence with antimuscarics was 98% and of life style interventions 50%. For treating stress urinary incontinence, the adherence to pelvic floor muscle training was 81% and to surgery 53%. CONCLUSIONS: Spanish urologist adherence to incontinence urinary guidelines is far from the ideal. Although this study may have bias, the outcome can be considered as representative of the situation. It is desirable that, in the process of guidelines creation, specific parameters to assess the degree of adherence be designed.